286 related articles for article (PubMed ID: 34827247)
1. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
[TBL] [Abstract][Full Text] [Related]
2. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
3.
Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
5.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Simner PJ; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
[TBL] [Abstract][Full Text] [Related]
9. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
11. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
12. Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of
Ballesté-Delpierre C; Ramírez Á; Muñoz L; Longshaw C; Roca I; Vila J
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203791
[TBL] [Abstract][Full Text] [Related]
13.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
14.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
[TBL] [Abstract][Full Text] [Related]
17. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany.
Kresken M; Korte-Berwanger M; Gatermann SG; Pfeifer Y; Pfennigwerth N; Seifert H; Werner G
Int J Antimicrob Agents; 2020 Oct; 56(4):106128. PubMed ID: 32758648
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018.
Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS
J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792
[TBL] [Abstract][Full Text] [Related]
20. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
Ghebremedhin B; Ahmad-Nejad P
Pathogens; 2021 Sep; 10(10):. PubMed ID: 34684208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]